See more : V-Mart Retail Limited (VMART.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Eupraxia Pharmaceuticals Inc. (EPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eupraxia Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ELTA Technology Co.,Ltd. (8487.TW) Income Statement Analysis – Financial Results
- Evoq Remedies Limited (EVOQ.BO) Income Statement Analysis – Financial Results
- Aura Energy Limited (AUEEF) Income Statement Analysis – Financial Results
- Munoth Capital Market Limited (MUNCAPM.BO) Income Statement Analysis – Financial Results
- Società Editoriale Il Fatto S.p.A. (ALSEI.PA) Income Statement Analysis – Financial Results
Eupraxia Pharmaceuticals Inc. (EPRX)
Industry: Biotechnology
Sector: Healthcare
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| Gross Profit | -209.91K | -193.27K | -111.53K | -116.81K | -201.94K | -125.83K | -85.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.54M | 17.20M | 9.68M | 859.78K | 2.94M | 6.64M | 3.19M |
| General & Administrative | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Other Expenses | 0.00 | 0.00 | -2.26M | 0.00 | 1.74K | 0.00 | 0.00 |
| Operating Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Cost & Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Interest Income | 407.04K | 569.32K | 65.73K | 427.00 | 12.04K | 1.11K | 330.00 |
| Interest Expense | 1.58M | 1.59M | 1.30M | 1.88M | 1.46M | 142.17K | 52.81K |
| Depreciation & Amortization | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| EBITDA | -36.75M | -22.14M | -21.96M | -2.01M | -5.94M | -14.57M | -4.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.90M | -22.63M | -20.87M | -2.25M | -6.15M | -14.31M | -4.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.29M | -64.07K | -5.46M | -1.76M | -1.08M | -2.95M | -143.13K |
| Income Before Tax | -39.18M | -23.92M | -23.37M | -4.01M | -7.24M | -14.83M | -5.00M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -89.67K | 930.52K | -1.34M | 1.87M | 1.40M | -1.46M | -627.56K |
| Net Income | -37.39M | -23.26M | -22.99M | -4.00M | -7.18M | -13.23M | -4.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EPS Diluted | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| Weighted Avg Shares Out | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
VICTORIA, BC , Sept. 19, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced...
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks The fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any...
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
VICTORIA, BC , Sept. 4, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that...
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
VICTORIA, BC , Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its...
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
The Company also provides an update on the Silicon Valley Bank convertible debt facility Including the new C$12 million convertible debt facility, Eupraxia anticipates it has sufficient cash to fund its operations to the second quarter of 2025 VICTORIA, BC...
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
VICTORIA, BC , July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. alone.
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
VICTORIA, BC , June 6, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that results...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansion Early low-dose cohorts showing meaningful improvement in patient symptoms and biological...
Source: https://incomestatements.info
Category: Stock Reports